medigraphic.com
ISSN 0001-0944 (Impreso)
Órgano Oficial de la Asociación Dental Mexicana

2007, Número 6

<< Anterior Siguiente >>

Rev ADM 2007; 64 (6)


Clindamicina para el tratamiento de infecciones dentales

Brook I, Lewis MAO, Sándor GKB, Jeffcoat M, Samaranayake LP, Vera RJ

Idioma: Español
Referencias bibliográficas: 43
Paginas: 230-237
Archivo PDF: 114.87 Kb.


RESUMEN

La clindamicina es un antibiótico de amplio espectro con actividad contra los aerobios grampositivos y una extensa gama de bacterias anaerobias, entre ellas los patógenos productores de betalactamasa. Los estudios in vitro e in vivo han demostrado que este fármaco alcanza una concentración elevada en el punto de infección, reduce la virulencia de las bacterias y refuerza las actividades fagocíticas de los linfocitos inmunitarios del huésped. La clindamicina por vía oral se absorbe con rapidez y eficacia, y su concentración permanece por encima de la concentración inhibidora mínima de la mayoría de los organismos por lo menos durante 6 horas. En este análisis, presentaremos pruebas de la eficacia e inocuidad de la clindamicina en el tratamiento de las infecciones odontogénicas con datos de estudios preclínicos y clínicos, los cuales avalan la aplicación general de este antibiótico como antiinfeccioso en el campo de la odontología.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Dajani AS, Taubert KA, Wilson W et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA 1997; 277: 1794-1801.

  2. Ehrenfeld M. Clindamycin in the treatment of dental infections. In: Zambrano D, editor. Clindamycin in the treatment of human infections. 2nd ed. Kalamazoo, Michigan: Pharmacia & Upjohn, 1997: 12-1-12-25.

  3. Sandor GKB, Low DE, Judd PL, Davidson RJ. Antimicrobial treatment options in the management of odontogenic infections. J Can Dent Assoc 1998; 64: 508-514.

  4. Novak E. Clindamycin: Clinical pharmacology. In: Zambrano D, editor. Clindamycin in the treatment of human infections. 2nd ed. Kalamazoo, Michigan: Pharmacia & Upjohn, 1997: 2-1-2-17.

  5. Tenson T, Lovmar M, Ehrenberg M. The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol 2003; 330: 1005-1014.

  6. McDonald PJ, Craig WA, Kunin CM. Persistent effect of antibiotics on Staphylococcus aureus after exposure for limited periods of time. J Infect Dis 1977; 135: 217-223.

  7. Eick S, Pfister W, Fiedler D, Straube E. Clindamycin promotes phagocytosis and intracellular killing of periodontopathogenic bacteria by crevicular granulocytes: an in vitro study. J Antimicrob Chemother 2000; 46: 583-588.

  8. Brook I, Gober AE, Leyva F. In vitro and in vivo effects of penicillin and clindamycin on expression of group A beta-hemolytic streptococcal capsule. Antimicrob Agents Chemother 1995; 39: 1565-1568.

  9. Santos JI, Arbo A, Pavia N. In vitro and in vivo effects of clindamycin on polymorphonuclear leukocyte function. Clin Ther 1992; 14: 578-594.

  10. Hand WL, Hand DL, King-Thompson NL. Antibiotic inhibition of the respiratory burst response in human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1990; 34: 863-870.

  11. Veringa EM, Lambe DW, Jr., Ferguson DA, Jr., Verhoef J. Enhancement of sonophagocytosis of Bacteroides spp. by clindamycin in subinhibitory concentrations. J Antimicrob Chemother 1989; 23: 577-587.

  12. McDonald PJ, Wetherall BL, Pruul H. Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes. Rev Infect Dis 1981; 3: 38-44.

  13. Gemmell CG, Amir MKA. Effect of certain antibiotics on the formation of cellular antigens and extracellular products by group-A streptococci. In: Parker MT, editor. Pathogenic Streptococci. Surrey, United Kingdom: Reedbooks Limited, 1978: 67-68.

  14. Bystedt H, DAhlback A, Dornbusch K, Nord CE. Concentrations of azidocillin, erythromycin, doxycycline and clindamycin in human mandibular bone. Int J Oral Surg 1978; 7: 442-449.

  15. Mueller SC, Henkel KO, Neumann J, Hehl EM, Gundlach KK, Drewelow B. Perioperative antibiotic prophylaxis in maxillofacial surgery: penetration of clindamycin into various tissues. J Craniomaxillofac Surg 1999; 27: 172-176.

  16. Oikarinen VJ, Malmstrom M. Penicillin V concentration in dental alveolar blood after tooth extraction. Scand J Dent Res 1972; 80: 279-284.

  17. Xue IB, Davey PG, Phillips G. Variation in postantibiotic effect of clindamycin against clinical isolates of Staphylococcus aureus and implications for dosing of patients with osteomyelitis. Antimicrob Agents Chemother 1996; 40: 1403-1407.

  18. Wang MG, Zhang YY, Zhu DM, Zhang J, Shi YG. Postantibiotic effects of eleven antimicrobials on five bacteria. Acta Pharmacol Sin 2001; 22: 804-808.

  19. Cleocin HCl [package insert]. Kalamazoo, Michigan: Pharmacia & Upjohn Company; 2003.

  20. Baker KA, Fotos PG. The management of odontogenic infections. A rationale for appropriate chemotherapy. Dent Clin North Am 1994; 38: 689-706.

  21. Silva J, Zambrano D. Clindamycin: Toxicity and side effects. In: Zambrano D, editor. Clindamycin in the treatment of human infections. 2nd ed. Pharmacia & Upjohn, 1997: 16-1-16-14.

  22. Levy DG, Stergachis A, McFarland LV, Van Vorst K, Graham DJ, Johnson ES, Park BJ, Shatin D, Clouse JC, Elmer GW. Antibiotics and Clostridium difficile diarrhea in the ambulatory care setting. Clin Ther 2000; 22: 91-102.

  23. Walker CB, Pappas JD, Tyler KZ, Cohen S, Gordon JM. Antibiotic susceptibilities of periodontal bacteria. In vitro susceptibilities to eight antimicrobial agents. J Periodontol 1985; 56: 67-74.

  24. Petri WA Jr, Mann BJ. Microbial adherence. In: Mandell GL, Bennett JE, Dolin R editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 5th ed. Philadelphia, Pennsylvania: Churchill Livingstone, 2000: 13-21.

  25. Sato M, Nagayama M, Yamaguchi R, Fujiwara S, Takeuchi H. Influence of secondary colonizers and human plasma on the adherence of Porphyromonas gingivalis in vitro. Eur J Oral Sci 2002; 110: 225-229.

  26. Sweeney LC, Dave J, Chambers PA, Heritage J. Antibiotic resistance in general dental practice—a cause for concern? J Antimicrob Chemother 2004; 53: 567-576.

  27. Rosen G, Nisimov I, Helcer M, Sela MN. Actinobacillus actinomycetemcomitans serotype b lipopolysaccharide mediates coaggregation with Fusobacterium nucleatum. Infect Immun 2003; 71: 3652-3656.

  28. Lewis MAO, Parkhurst CL, Douglas CWI, Martin MV, Absi EG, Bishop PA, Jones SA. Prevalence of penicillin resistant bacteria in acute suppurative oral infection. J Antimicrob Chemother 1995; 35: 785-791.

  29. Kirkwood KL. Update on antibiotics used to treat orofacial infections. Alpha Omegan 2003; 96: 28-34.

  30. Gilmore WC, Jacobus NV, Gorbach SL, Doku HC, Tally FP. A prospective double-blind evaluation of penicillin versus clindamycin in the treatment of odontogenic infections. J Oral Maxillofac Surg 1988; 46: 1065-1070.

  31. Mangundjaja S, Hardjawinata K. Clindamycin versus ampicillin in the treatment of odontogenic infections. Clin Ther 1990; 12: 242-249.

  32. von Konow L, Köndell PÅ, Nord CE, Heimdahl A. Clindamycin versus phenoxymethylpenicillin in the treatment of acute orofacial infections. Eur J Clin Microbiol Infect Dis 1992; 11: 1129-1135.

  33. Schuen NJ, Panzer JD, Atkinson WH. A comparison of clindamycin and penicillin V in the treatment of oral infections. J Oral Surg 1974; 32: 503-505.

  34. Mangundjaja S, Hardjawinata K. Clindamycin alone compared with clindamycin plus ibuprofen for odontogenic infections. Curr Ther Res 1996; 57: 913-926.

  35. Kannangara DW, Thadepalli H, McQuirter JL. Bacteriology and treatment of dental infections. Oral Surg Oral Med Oral Pathol 1980; 50: 103-109.

  36. Walker CB, Gordon JM, Cornwall HA, Murphy JC, Socransky SS. Gingival crevicular fluid levels of clindamycin compared with its minimal inhibitory concentrations for periodontal bacteria. Antimicrob Agents Chemother 1981; 19: 867-871.

  37. Gordon J, Walker C, Lamster I, West T, Socransky S, Seiger M, Fasciano R. Efficacy of clindamycin hydrochloride in refractory periodontitis. 12-month results. J Periodontol 1985; 56(suppl): 75-80.

  38. Gordon J, Walker C, Hovliaras C, Socransky S. Efficacy of clindamycin hydrochloride in refractory periodontitis: 24-month results. J Periodontol 1990; 61: 686-691.

  39. Trieger N, Mark L, McKitrick J, Fiorillo J, Van Horn K, Motyl M. Clindamycin v. tetracycline in the surgical treatment of advanced periodontitis: a double blind study with applicability for implant salvage. Int J Oral Implantol 1991; 7: 31-38.

  40. Sigusch B, Beier M, Klinger G, Pfister W, Glockmann E. A 2-step non-surgical procedure and systemic antibiotics in the treatment of rapidly progressive periodontitis. J Periodontol 2001; 72: 275-283.

  41. Walker C, Gordon J. The effect of clindamycin on the microbiota associated with refractory periodontitis. J Periodontol 1990; 61: 692-698.

  42. Brook I, Douma M. Antimicrobial therapy guide for the dentist. Newtown, Pennsylvania: Handbooks in Health Care Co. 2004: 1-230.

  43. Wiesenbaugh JM, Jr. Comparison of oral penicillin G and clindamycin as prophylactic antibiotics in oral surgery. Oral Surg Oral Med Oral Pathol 1971; 31: 302-311.




2020     |     www.medigraphic.com